Management of pulmonary embolism in 2005.
Davidson
Bruce L
BL
Tomkowski
Witold Z
WZ
D000925:Anticoagulants / Q000627:therapeutic use*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D000077425:Fondaparinux; D006207:Half-Life; D006493:Heparin / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D010100:Oxygen / Q000008:administration & dosage; D011134:Polysaccharides / Q000493:pharmacokinetics / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D011134:Polysaccharides; C036309:fibrin fragment D; D014812:Vitamin K; D006493:Heparin; D000077425:Fondaparinux; D010100:Oxygen